This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JP Morgan Launches Minimum Volatility ETF
by Zacks Equity Research
JP Morgan rolls out minimum volatility US equity ETF.
Lilly Reports Mixed Results from Late-Stage Cyramza Study
by Zacks Equity Research
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
by Zacks Equity Research
Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
by Arpita Dutt
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Sanofi Begins Combo Studies on Multiple Myeloma Candidate
by Zacks Equity Research
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
by Zacks Equity Research
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
Roche's Avastin Gets Full FDA Approval for Brain Cancer
by Zacks Equity Research
Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
by Zacks Equity Research
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study
by Zacks Equity Research
AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.
Sanofi's Toujeo Meets Key Objective in Head-to-Head Study
by Zacks Equity Research
Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
by Zacks Equity Research
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention
by Zacks Equity Research
Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.
3 Drug/Biotech Stocks in Focus on World AIDS Day
by Zacks Equity Research
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Gilead & 3 Other Drug Stocks in Focus this World AIDS Day
by Arpita Dutt
With 36.7 million people living with HIV, there remains significant need for new and improved drugs in this corner of the market that has players like Gilead (GILD).
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained 32.1% so far in the second half of the year supported by a series of positive news in the past few months.
How Will U.S. Tax Reform Impact Pharma/Biotech Industry?
by Zacks Equity Research
After certain modifications to the original plan over the past year, the tax reform bill is expected to be voted on by the Congress this week. Let's see how this vote will impact the pharma/biotech industry.
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%
by Zacks Equity Research
Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.
Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study
by Zacks Equity Research
Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche
J&J & Glaxo's Juluca Approval Puts Spotlight on HIV Space (Revised)
by Zacks Equity Research
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry
by Zacks Equity Research
Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.